Literature DB >> 7533088

Antibody ligation of CD7 leads to association with phosphoinositide 3-kinase and phosphatidylinositol 3,4,5-trisphosphate formation in T lymphocytes.

S G Ward1, R Parry, C LeFeuvre, D M Sansom, J Westwick, A I Lazarovits.   

Abstract

The CD7 40-kDa glycoprotein is present on a major subset of human T cells and in the presence of phorbol esters mediates an accessory pathway of T cell activation. Hitherto, the intracellular events elicited by CD7 have been ill-defined. This report demonstrates that cross-linking of CD7 results in the formation of phosphatidic acid in the absence of phosphatidylinositol-4,5-bisphosphate metabolism and also the formation of D-3 phosphoinositides lipids which have been postulated to act as intracellular regulatory molecules. The magnitude of D-3 phosphoinositide formation was similar to that induced by CD3. Both the CD7- and CD3-induced elevation of phosphatidylinositol 3,4,5-trisphosphate approximately 5-10 fold less than that elicited by ligation of the costimulatory molecule CD28 by its counter receptor CD80. The formation of D-3 phosphoinositides following ligation of CD7 coincided with the co-association of CD7 with phosphoinositide 3-kinase, the enzyme which mediates the formation of D-3 phosphoinositide lipids. In contrast, ligation of another reported T cell accessory molecule CD5, failed to elicit formation of D-3 phosphoinositides, implying that phosphoinositide 3-kinase is not coupled to all T cell molecules with accessory functions. Since D-3 phosphoinositides have been suggested to play a pivotal role in T cell costimulatory signals induced by CD28, the results presented in this study suggest that CD7 may also influence T cell activation via this pathway.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7533088     DOI: 10.1002/eji.1830250229

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  7 in total

Review 1.  T cell signal transduction and the role of CD7 in costimulation.

Authors:  R Stillwell; B E Bierer
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

Review 2.  Hematopoietic Cell Transplantation and Adoptive Cell Therapy in Peripheral T Cell Lymphoma.

Authors:  Andrew M Rogers; Jonathan E Brammer
Journal:  Curr Hematol Malig Rep       Date:  2020-08       Impact factor: 3.952

3.  CD7-negative T cells represent a separate differentiation pathway in a subset of post-thymic helper T cells.

Authors:  U Reinhold; L Liu; J Sesterhenn; H Abken
Journal:  Immunology       Date:  1996-11       Impact factor: 7.397

4.  CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies.

Authors:  Diogo Gomes-Silva; Madhuwanti Srinivasan; Sandhya Sharma; Ciaran M Lee; Dimitrios L Wagner; Timothy H Davis; Rayne H Rouce; Gang Bao; Malcolm K Brenner; Maksim Mamonkin
Journal:  Blood       Date:  2017-05-24       Impact factor: 22.113

5.  Molecular cloning and expression analysis of pig CD7.

Authors:  Ju Yeon Lee; Joonbeom Bae; Inho Choi; Chung-Gyu Park; Taehoon Chun
Journal:  Vet Res Commun       Date:  2014-05-03       Impact factor: 2.459

Review 6.  CD28: a signalling perspective.

Authors:  S G Ward
Journal:  Biochem J       Date:  1996-09-01       Impact factor: 3.857

7.  SECTM1 produced by tumor cells attracts human monocytes via CD7-mediated activation of the PI3K pathway.

Authors:  Tao Wang; Yingbin Ge; Min Xiao; Alfonso Lopez-Coral; Ling Li; Alexander Roesch; Catherine Huang; Peter Alexander; Thomas Vogt; Xiaowei Xu; Wei-Ting Hwang; Melissa Lieu; Eric Belser; Rui Liu; Rajasekharan Somasundaram; Meenhard Herlyn; Russel E Kaufman
Journal:  J Invest Dermatol       Date:  2013-10-24       Impact factor: 8.551

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.